Evaluation of the Effect of Rosiglitazone on Endothelium Function of Aorta in Type 2 Diabetes by High-Frequency Ultrasound

[Objective]To evaluate the effect of rosiglitazone on brachial artery endothelial function.[Methods]Forty three type 2 diabetes patients were divided into rosiglitazone group(receiving 4mg rosiglitazone once a day) and control group (receiving conventional treatment). Flow mediated dilation (FMD) and nitroglycerine mediated dilation (NTGMD) in the right brachial artery was evaluated by high-frequency ultrasound before and after taking rosiglitazone for 3 months. BMI, blood pressure, blood lipid and urine albumin were measured. [Results] Compared with control group, blood pressure and urine albumin decreased significantly, and FMD improved significantly in rosiglitazone group, but there was no significant difference in the change of NTGMD between the two groups.[Conclusion]Rosiglitazone can significantly improve the endothelial function, and alleviate the blood pressure and urine albumin in the patients with type 2 diabetes.